Exicure Inc. uses its proprietary SNA technology to develop therapies for neurological disorders and hair loss with its lead program candidate, SCN9A, in preclinical studies. The company has entered agreements with AbbVie Inc. for hair loss disorders development and Ipsen S.A. for researching, developing and commercializing novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Founded in 2011, Exicure is based in Chicago, Illinois.